Joten-M Forte Tablet is a fixed-dose combination medication containing Metformin 1000 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class antihyperglycemic agent, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to achieve better glycemic control, reducing fasting and postprandial blood glucose levels. Joten-M Forte is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low unless combined with other antidiabetic agents. Regular monitoring of glycemic parameters and renal function is recommended during therapy to ensure safety and efficacy.